

Amendments to the Specification

Please amend the specification as follows:

Please amend the SEQUENCE LISTING appearing immediately after page 230 of the present application to read as follows:

SEQUENCE LISTING

<110> **Macrogenics, Inc.**
Koenig, Scott
Veri, Maria Concetta

<120> FcGammaRIIB Specific Antibodies and Uses Thereof

<130> **11183-003-999 1301.0012CN1**

<150> 10643857
<151> 2003-08-14

<150> **10/524,134 10534124**
<151> 2005-02-11

<150> **60/403,266 60403266**
<151> 2002-08-14

<150> PCT/US03/25399
<151> 2003-08-14

<160> 13

<170> PatentIn version **3.2 3.4**

<210> 1
<211> 363
<212> DNA
<213> homo sapiens

<400> 1
cagggtccaat tgcagcagcc tgtgactgag ctggtgaggc cgggggcttc agtgatgttg 60
tcttgcaagg cttctgacta cccttcacc aactactgga tacactgggt aaagcagagg 120
cctggacaag gcctggagtg gatcgagtg attgatcctt ctgatactta tccaaattac 180
aataaaaaagt tcaagggcaa ggccacattg actgtagtcg tctcctccag cacagcctac 240
atgcagctca gcagcctgac atctgacgat tctgcggtct attactgtgc aagaaacggt 300

gattccgatt attactctgg tatggactac tggggtaag gaacctcagt cacgcgtccc 360

tca 363

<210> 2
<211> 121
<212> PRT
<213> homo sapiens

<400> 2

Gln Val Gln Leu Gln Gln Pro Val Thr Glu Leu Val Arg Pro Gly Ala
1 5 10 15

Ser Val Met Leu Ser Cys Lys Ala Ser Asp Tyr Pro Phe Thr Asn Tyr
20 25 30

Trp Ile His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Val Ile Asp Pro Ser Asp Thr Tyr Pro Asn Tyr Asn Lys Lys Phe
50 55 60

Lys Gly Lys Ala Thr Leu Thr Val Val Val Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Asn Gly Asp Ser Asp Tyr Tyr Ser Gly Met Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Ser Val Thr Val Ser Ser
115 120

<210> 3
<211> 321
<212> DNA
<213> homo sapiens

<400> 3
gacatcttgc tgactcagtc tccagccatc ctgtctgtga gtccaggaga gagagtcagt 60

ttttcctgca ggaccagtca gagcattggc acaaacatac actggtatca gcaaagaaca 120
aatggttttc caaggcttct cataaagaat gtttctgagt ctatctctgg gatcccttcc 180
agggtttagt gcagtggatc agggacagat tttattctta gcatcaacag tgtggagtct 240
gaagatattg cagattatta ttgtcaacaa agtaatacct ggccgttcac gttcggaggg 300
gggaccaagc tggaaataaa a 321

<210> 4
<211> 107
<212> PRT
<213> homo sapiens

<400> 4

Asp Ile Leu Leu Thr Gln Ser Pro Ala Ile Leu Ser Val Ser Pro Gly
1 5 10 15

Glu Arg Val Ser Phe Ser Cys Arg Thr Ser Gln Ser Ile Gly Thr Asn
20 25 30

Ile His Trp Tyr Gln Gln Arg Thr Asn Gly Phe Pro Arg Leu Leu Ile
35 40 45

Lys Asn Val Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Ile Leu Ser Ile Asn Ser Val Glu Ser
65 70 75 80

Glu Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Ser Asn Thr Trp Pro Phe
85 90 95

Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys
100 105

<210> 5
<211> 9
<212> PRT
<213> artificial

<220>
<223> fusion protein-partial sequence

<400> 5

Lys Lys Phe Ser Arg Ser Asp Pro Asn
1 5

<210> 6
<211> 9
<212> PRT
<213> artificial

<220>
<223> fusion protein-partial sequence

<400> 6

Gln Lys Phe Ser Arg Leu Asp Pro Asn
1 5

<210> 7
<211> 9
<212> PRT
<213> artificial

<220>
<223> fusion protein-partial sequence

<400> 7

Gln Lys Phe Ser Arg Leu Asp Pro Thr
1 5

<210> 8
<211> 9
<212> PRT
<213> artificial

<220>
<223> fusion protein-partial sequence

<400> 8

Lys Lys Phe Ser Arg Leu Asp Pro Thr
1 5

<210> 9
<211> 9
<212> PRT
<213> artificial

<220>
<223> fusion protein-partial sequence

<400> 9

~~Gln Lys Phe Ser Arg Leu Asp Pro Thr~~
Gln Lys Phe Ser His Leu Asp Pro Thr
1 5

<210> 10
<211> 9
<212> PRT
<213> artificial

<220>
<223> fusion protein-partial sequence

<400> 10

Lys Lys Phe Ser His Leu Asp Pro Thr
1 5

<210> 11
<211> 8
<212> PRT
<213> artificial

<220>
<223> fusion protein-partial sequence

<220>
<221> MISC_FEATURE
<222> (4)..(6)
<223> X may be any amino acid

<400> 11

Ala Pro Ser Xaa Xaa Xaa Ser Ser
1 5

<210> 12
<211> 8
<212> PRT

<213> artificial

<220>

<223> fusion protein-partial sequence

<400> 12

Val Pro Ser Met Gly Ser Ser Ser
1 5

<210> 13

<211> 7

<212> PRT

<213> artificial

<220>

<223> FcgammaRIIB2 isoform (positions 135-141)

<400> 13

Ser Asp Pro Asn Phe Ser Ile
1 5